ASH 2015 Coverage: The Meaning of a Second-Generation BTK Inhibitor for Patients Watch patient advocate Carol Preston, on location at the 2015 American Society of Hematology (ASH) conference, discusses the new molecule, ACP-196, a second-generation BTK inhibitor, with CLL expert Dr. Kathryn Kolibaba. Dr. Kolibaba describes this new molecule’s function including its potential for decreased side effects and her hopes for the future. “Never,” exclaims Dr. Kolibaba, “have we had a better menu of options. Never have we had hope like we do now for a cure.” Get email alerts | Subscribe on YouTube | Like on Facebook | Follow on Twitter | Follow on Google+ |